# Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors

Source: https://onco.cc/trials/nct07030257/  
OnCo record `nct07030257` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of CP-383 in colorectal cancer, small-cell lung cancer, head and neck squamous cell carcinoma, bladder & urothelial cancer, non-small-cell lung cancer and pancreatic ductal adenocarcinoma, run by Tasca Therapeutics, now recruiting.

## Summary

Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors is a phase 1/2 interventional study registered as NCT07030257 by Tasca Therapeutics, with 150 participants planned, started 2025-08-27 and due to reach its primary completion in 2028-08-15. Interventions recorded: CP-383.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07030257
- Phase: 1/2
- Setting: A Multi-Center, Open Label, Phase 1/2 Study of CP-383, in Patients With Advanced or Metastatic Solid Tumors
- Sponsor: Tasca Therapeutics
- Enrolled: 150

## Sources

- ClinicalTrials.gov NCT07030257: https://clinicaltrials.gov/study/NCT07030257

## Connected records

- cancers: [Bladder & urothelial cancer](https://onco.cc/cancers/urothelial/), [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)

---
JSON: https://onco.cc/api/v1/entities/nct07030257.json